---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-125195"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:46:52.663599+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics appoints Ronald A. Andrews to board; Robert Lenk resigns

## Summary
- Robert Lenk resigned as director and Nominating Committee member effective March 20, 2026; no policy disagreement cited.
- Ronald A. Andrews appointed to fill vacancy, effective immediately; will stand for reelection at 2026 annual meeting.
- Andrews is independent under Nasdaq rules; appointed to Nominating and Corporate Governance Committee.
- Andrews brings 35+ years in diagnostics; currently Founder/Managing Partner of The Bethesda Group.
- No transactions requiring SEC disclosure; standard indemnification agreement expected.

## SEC filing metadata
- accession: 0001193125-26-125195
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/0001193125-26-125195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/pstv-20260320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-125195
- JSON: https://secwatch.observer/filing/0001193125-26-125195.json
- Plain text: https://secwatch.observer/filing/0001193125-26-125195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.